Used in pharmaceutical research as a potent inhibitor of Janus kinase (JAK), particularly JAK1, for the treatment of autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Its selective inhibition helps reduce cytokine signaling involved in immune responses, offering therapeutic benefits with potentially fewer side effects compared to broad-spectrum immunosuppressants. Also investigated for oncology applications due to JAK pathway involvement in certain hematologic malignancies. Suitable for formulation in oral dosage forms owing to favorable pharmacokinetic properties.